Anyone who is sexually active should be informed about PrEP1
Who could benefit from PrEP?
PrEP is for sexually active adults or adolescents who are HIV negative, including1,2:
- Men, transgender men,* women,* pregnant women,* transgender women, and nonbinary individuals who may need or want PrEP
- Individuals of any sexual orientation or relationship status
- Anyone who asks for it, even if there are no identified risk factors after a sexual health assessment
PrEP is not only for gay men.1
PrEP can be beneficial to many individuals.
Heterosexual contact accounted for
of the 37,449 estimated new HIV diagnoses in the US.3
(According to 2022 CDC estimates.)
*Not all PrEP medications can be used in cisgender women or transgender men.2
Populations most impacted by HIV
Certain populations are disproportionately impacted by HIV and should be considered for PrEP discussions.4
According to CDC 2021 and 2022 estimates:
Young individuals accounted for
Black communities accounted for
of all new HIV diagnoses3*
Black men who have sex with men (MSM) have a
lifetime likelihood of acquiring HIV4†
Black cisgender women accounted for
of all new HIV diagnoses among all cisgender women5*
Black transgender women accounted for
of HIV infections among transgender women with HIV living in 7 major US cities6*
Latinx/o communities accounted for
of all new HIV diagnoses3*
Latinx/o men who have sex with men (MSM) have a
likelihood of acquiring HIV4†
Of new HIV diagnoses in the US,
were women3*
Among all PrEP users in the US in 2021,
were male3‡ and only
were female3‡
Transgender women are
more likely to have HIV than the general population7§
Transgender men are
more likely to have HIV than the general population7§
*CDC, 2022. Estimates for individuals aged ≥13 years (who were PrEP eligible).3
†Singh S, et al; CROI 2024. Based on CDC estimates established from HIV diagnosis and death rates; 2017 to 2021.4
‡CDC, 2021. Estimates for individuals aged ≥16 years (who were PrEP eligible).3
§Stutterheim SE, et al; 2021. Based on a meta-analysis of 98 studies in individuals aged >15 years; N=48,604.7
Test your PrEP and HIV prevention knowledge.
PrEP isn’t only for gay men. Who else may want or need PrEP?
*Not all PrEP medications can be used in cisgender women or transgender men.2
Correct!Incorrect.PrEP should be discussed with all adults and adolescents who are sexually active, including cisgender men and women, transgender men and women, and nonbinary individuals. Some PrEP options can be used in pregnant women.2
Individuals who are part of the following populations could be disproportionately impacted by HIV and may need or want the PrEP discussion.
Correct!Incorrect.PrEP conversations should be prioritized in all of these populations.8-10
Most primary care providers are discussing PrEP with individuals in their practice.
Correct!Incorrect.Primary care providers are discussing PrEP and accounted for 80% of PrEP prescriptions.11
References:
1. Centers for Disease Control and Prevention. US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 Update: a clinical practice guideline. Accessed September 12, 2024. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf
2. Centers for Disease Control and Prevention. HIV Nexus: CDC resources for clinicians. Updated August 20, 2024. Accessed September 4, 2024. https://www.cdc.gov/hivnexus/hcp/prep/index.html
3. Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through June 2023; and preexposure prophylaxis (PrEP) data reported through March 2023. HIV Surveillance Data Tables 2023;4(3). Published October 2023. Accessed September 12, 2024. https://stacks.cdc.gov/view/cdc/136159
4. Singh S. Estimating lifetime risk of a diagnosis of HIV infection among MSM: United States, 2017-2021. Abstract presented at: Conference on Retroviruses and Opportunistic Infections (CROI); March 3-6, 2024; Denver, CO.
5. Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States in Black/African American females, 2022: Tables. Accessed September 12, 2024. https://gis.cdc.gov/grasp/nchhstpatlas/tables.html
6. Centers for Disease Control and Prevention. HIV infection, risk, prevention, and testing behaviors among transgender women—National HIV Behavioral Surveillance, 7 U.S. cities, 2019-2020. HIV Surveillance Special Report 27. Published April 2021. Accessed September 12, 2024. https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-special-report-number-27.pdf
7. Stutterheim SE, van Dijk M, Wang H, Jonas KJ. The worldwide burden of HIV in transgender individuals: an updated systematic review and meta-analysis. PLoS One. 2021;16(12):e0260063. doi:10.1371/journal.pone.0260063
8. Centers for Disease Control and Prevention. HIV prevention in the United States: mobilizing to end the epidemic. Published October 2021. Accessed September 12, 2024. https://www.cdc.gov/hiv/pdf/policies/cdc-hiv-prevention-bluebook.pdf
9. Sullivan PS, DuBose SN, Castel AD, et al. Equity of PrEP uptake by race, ethnicity, sex and region in the United States in the first decade of PrEP: a population-based analysis. Lancet Reg Health Am. 2024;33:100738.
10. Bosh KA, Hall HI, Eastham L, Daskalakis DC, Mermin HJ. Morbidity and Mortality Weekly Report (MMWR): Estimated annual number of HIV infections—United States, 1981-2019. Centers for Disease Control and Prevention. Published June 4, 2021. Accessed September 12, 2024. https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7022a1-H.pdf
11. Data on file. Gilead Sciences, Inc.